Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Down – What’s Next?

by · The Cerbat Gem

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) shares gapped down prior to trading on Wednesday . The stock had previously closed at $8.89, but opened at $8.48. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $8.51, with a volume of 3,794 shares trading hands.

Shionogi & Co., Ltd. Unsponsored ADR Stock Performance

The company has a market capitalization of $14.44 billion, a P/E ratio of 13.27, a P/E/G ratio of 2.01 and a beta of 0.20. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.44 and a quick ratio of 5.74. The stock’s 50 day simple moving average is $8.38 and its two-hundred day simple moving average is $8.56.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) last announced its earnings results on Monday, October 27th. The company reported $0.18 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.16 by $0.02. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 39.53% and a return on equity of 11.90%. The company had revenue of $740.85 million for the quarter, compared to analyst estimates of $742.35 million. As a group, research analysts expect that Shionogi & Co., Ltd. Unsponsored ADR will post 0.66 earnings per share for the current year.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

(Get Free Report)

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.

Read More